Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy

Trial Profile

Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2017

At a glance

  • Drugs Pamrevlumab (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Sponsors FibroGen
  • Most Recent Events

    • 10 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 Jul 2019.
    • 10 Apr 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.
    • 06 Jan 2016 According to a FibroGen media release, the company enrolled its first two patients in this trial, in January 2016. An interim analysis of the study will be performed after all evaluable subjects complete one year of dosing. If the interim analysis indicates a potential benefit from FG-3019, the study will be extended to two years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top